HUMAN LUNG SURFACTANT DEFICIENCY^DIAGNOSIS AND THERAPY

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$405,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Agency Tracking Number:
3118
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
California Biotechnology Inc.
Po Box 51650, Palo Alto, CA, 94306
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Barbara Cordell
Principal Investigator
(415) 966-1550
Business Contact:
() -
Research Institution:
n/a
Abstract
THIS PROPOSAL DESCRIBES THE DEVELOPMENT OF A MODERN DIAGNOSTIC TEST AND THERAPY FOR INFANT RESPIRATORY DISTRESS SYNDROME (RDS). RDS IS THE LEADING CAUSE OF NEONATE MORTALITY AND MORBIDITY. IT IS DUE TO INADEQUATE LEVELS OF LUNG SURFACTANT, A LIPID-PROTEIN COMPLEX ESSENTIAL FOR LUNG INFLATION. CURRENT DIAGNOSTIC ASSAYS ARE BASED ON THE LIPID COMPONENT OF SURFACTANT AND ARE UNRELIABLE. WE PROPOSE TO DEVELOP A SENSITIVE AND ACCURATE ENZYME-LINKED IMMUNOADSORBENT ASSAY DIRECTED AGAINST THE MAJOR PROTEIN COMPONENT OF SURFACTANT. RDS IS NOW TREATED WITH A RESPIRATOR UNTIL SURFACTANT DEVELOPS, YET THIS OFTEN LEADS TO LUNG DISORDERS. NATURAL SURFACTANT HAS BEEN SUCCESSFULLY ADMINISTERED AS A THERAPY BUT LIMITED AVAILABILITY MAKES THIS APPROACH IMPRACTICABLE FOR ROUTINE THERAPY. RECOMBINANT DNA TECHNOLOGY WILL BE USED TO PRODUCE THE NEEDED SURFACTANT PROTEIN. THE HUMAN GENE ENCODING THE PROTEIN WILL BE CLONED AND EXPRESSED, AND THE APOPROTEIN CONSTITUTED WITH LIPIDS TO PROVIDE A SAFE AND EFFECTIVE THERAPY.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government